Search

Your search keyword '"Woermann B"' showing total 884 results

Search Constraints

Start Over You searched for: Author "Woermann B" Remove constraint Author: "Woermann B"
884 results on '"Woermann B"'

Search Results

3. Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia

4. Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities

10. Hematopoietic Growth Factors: Supportive and Priming Effects in AML

12. Failure of Fluconazole Prophylaxis to Reduce Mortality During Treatment for Refractory Acute Myeloid Leukemia: Results of a Phase III Multicenter Study

15. Granulocyte Colony-Stimulating Factor Improves the Antileukemic Efficacy of the Sequential High-Dose Cytosine Arabinoside and Mitoxantrone Regimen (S-HAM) in Patients Younger than 60 Years with High-Risk Acute Myeloid Leukemia

16. Superiority of High-Dose over Intermediate-Dose Cytosine Arabinoside (AraC) in the Treatment of Patients with High-Risk Acute Myeloid Leukemia (AML)

18. All-Trans Retinoic Acid (ATRA) Combined with Double Induction Strategy in Acute Promyelocytic Leukemia (APL). Preliminary Results

19. Biologic Determinants for AML Therapy

22. Growth Factors in AML: Updates

23. Fludarabine and Fludarabine, Mitoxantrone, Dexamethasone in the Management of Low-Grade Non-Hodgkin Lymphomas

25. Correlation of Deoxycytidine Deaminase, Thymidine Kinase and Polymerase Alpha Activity and Deoxycytidine Deaminase Gene Expression In Vivo with Clinical Response to TAD-9+GM-CSF Induction Therapy in Acute Myeloid Leukemia

26. Characterization of Normal and Leukemic Lymphohematopoietic Precursor Cells by Three-Color Flow Cytometry and Detection of Clone-Specific Leukemia-Associated T-Cell Receptor δ Rearrangements

30. Preliminary Results of a Placebo-Controlled, Double-Blind Trial Evaluating Sequential HD-AraC/Mitoxantrone Induction Chemotherapy with or Without Granulocyte-Macrophage Colony-Stimulating Factor in Patients with High-Risk Myelodysplastic Syndromes

32. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)

34. Interleukin-2 Postremission Therapy in Acute Myeloid Leukemia (AML): In Vitro and In Vivo Effects of a Five Day Continuous Infusion of IL-2 on Phenotype and Function of Peripheral Lymphocytes

35. S-HAM Salvage Therapy of Relapsed and Refractory AML Followed by Interleukin 2 Postremission Therapy

37. Hematologic and Therapeutic Effects of High-Dose AraC/Mitoxantrone (HAM) in the Induction Treatment of Patients with Newly Diagnosed AML. A Trial by AML Cooperative Group

38. Fludarabine in Combination with Mitoxantrone and Dexamethasone in Relapsed and Refractory Low-Grade Non-Hodgkin’s Lymphoma

39. Heterogeneity of HRX-FEL Fusion Transcripts in Adult and Pediatric t(4;11) ALL

47. Chemotherapy Intensity and Long-Term Outcome in AML

48. Biology Oriented Investigation of Treatment Strategies for Acute Myeloid Leukemia (AML): The AMLCG Approach

49. FS-HAI for Relapsed AML

Catalog

Books, media, physical & digital resources